Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine
Introduction: Basal and intermediate insulin is available as U-100 (glargine, determir, NPH) or ultra-long-acting (ULA) U-200 (degludec) or U-300 (glargine). Insulins may be substituted with other insulin formulations based on financial factors, formulary preferences, patient preference, and patient...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Journal of Primary Care & Community Health |
| Online Access: | https://doi.org/10.1177/21501319251327318 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850275462499008512 |
|---|---|
| author | Natalie Rosario Cami Hunger Allison Pettijohn K’bria Whaley Andrea Pabon Valeria Hohl Bernadette Asias-Dinh Jodie Gee Joshua Wollen |
| author_facet | Natalie Rosario Cami Hunger Allison Pettijohn K’bria Whaley Andrea Pabon Valeria Hohl Bernadette Asias-Dinh Jodie Gee Joshua Wollen |
| author_sort | Natalie Rosario |
| collection | DOAJ |
| description | Introduction: Basal and intermediate insulin is available as U-100 (glargine, determir, NPH) or ultra-long-acting (ULA) U-200 (degludec) or U-300 (glargine). Insulins may be substituted with other insulin formulations based on financial factors, formulary preferences, patient preference, and patient response. Objective: Evaluate the impact on total daily dose of insulin when switching from an intermediate or basal U-100 to a ULA insulin. Methods: A single-center retrospective chart review was performed at a federally qualified health center. Patients switched from a U-100 intermediate or basal insulin to a U-200 degludec or U-300 glargine ULA insulin from 2019 to March 2024 were assessed. Clinical measures assessed were initial intermediate or basal insulin total daily dose, ULA insulin total daily dose at time of switch, at 1, 3, and 6 months, and change in HgbA1c, BMI, and weight. Results: When switched from a U-100 to a U-200 or U-300 insulin ( n = 53), basal insulin total daily dose decreased by 13.1 units at 6 months ( P < .05). At the 6-month mark after ULA switch, HgbA1c decreased ( P < .001), but BMI ( P = .161) and weight ( P = .076) were similar. HgbA1c, BMI, weight, and total daily insulin dose were not significantly different between patients assigned U-200 and U-300 insulins. Conclusion: Patients switched from a U-100 basal insulin may utilize a lower total daily dose of a ULA insulin and experience reductions in HgbA1c, BMI, and weight. |
| format | Article |
| id | doaj-art-9373797e99a94dfda3b83eb1934286a8 |
| institution | OA Journals |
| issn | 2150-1327 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Primary Care & Community Health |
| spelling | doaj-art-9373797e99a94dfda3b83eb1934286a82025-08-20T01:50:44ZengSAGE PublishingJournal of Primary Care & Community Health2150-13272025-03-011610.1177/21501319251327318Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin GlargineNatalie Rosario0Cami Hunger1Allison Pettijohn2K’bria Whaley3Andrea Pabon4Valeria Hohl5Bernadette Asias-Dinh6Jodie Gee7Joshua Wollen8Vecino’s Denver Harbor Family Health Centers, Houston, TX, USAUniversity of Houston College of Pharmacy, Houston, TX, USAUniversity of Houston College of Pharmacy, Houston, TX, USAUniversity of Houston College of Pharmacy, Houston, TX, USAUniversity of Houston College of Pharmacy, Houston, TX, USAUniversity of Houston College of Pharmacy, Houston, TX, USAVecino’s Denver Harbor Family Health Centers, Houston, TX, USAVecino’s Denver Harbor Family Health Centers, Houston, TX, USAUniversity of Houston College of Pharmacy, Houston, TX, USAIntroduction: Basal and intermediate insulin is available as U-100 (glargine, determir, NPH) or ultra-long-acting (ULA) U-200 (degludec) or U-300 (glargine). Insulins may be substituted with other insulin formulations based on financial factors, formulary preferences, patient preference, and patient response. Objective: Evaluate the impact on total daily dose of insulin when switching from an intermediate or basal U-100 to a ULA insulin. Methods: A single-center retrospective chart review was performed at a federally qualified health center. Patients switched from a U-100 intermediate or basal insulin to a U-200 degludec or U-300 glargine ULA insulin from 2019 to March 2024 were assessed. Clinical measures assessed were initial intermediate or basal insulin total daily dose, ULA insulin total daily dose at time of switch, at 1, 3, and 6 months, and change in HgbA1c, BMI, and weight. Results: When switched from a U-100 to a U-200 or U-300 insulin ( n = 53), basal insulin total daily dose decreased by 13.1 units at 6 months ( P < .05). At the 6-month mark after ULA switch, HgbA1c decreased ( P < .001), but BMI ( P = .161) and weight ( P = .076) were similar. HgbA1c, BMI, weight, and total daily insulin dose were not significantly different between patients assigned U-200 and U-300 insulins. Conclusion: Patients switched from a U-100 basal insulin may utilize a lower total daily dose of a ULA insulin and experience reductions in HgbA1c, BMI, and weight.https://doi.org/10.1177/21501319251327318 |
| spellingShingle | Natalie Rosario Cami Hunger Allison Pettijohn K’bria Whaley Andrea Pabon Valeria Hohl Bernadette Asias-Dinh Jodie Gee Joshua Wollen Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine Journal of Primary Care & Community Health |
| title | Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine |
| title_full | Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine |
| title_fullStr | Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine |
| title_full_unstemmed | Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine |
| title_short | Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine |
| title_sort | clinical outcomes of switching u 100 intermediate or basal insulin to u 200 insulin degludec or u 300 insulin glargine |
| url | https://doi.org/10.1177/21501319251327318 |
| work_keys_str_mv | AT natalierosario clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT camihunger clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT allisonpettijohn clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT kbriawhaley clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT andreapabon clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT valeriahohl clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT bernadetteasiasdinh clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT jodiegee clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine AT joshuawollen clinicaloutcomesofswitchingu100intermediateorbasalinsulintou200insulindegludecoru300insulinglargine |